Jennifer R. Devlin

Jennifer R. Devlin

Auto-generated profile, based on publicly available information

Jennifer R. Devlin

The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2021 in Cell
Verified
Journal Article
Closed access
SVStephin J. Vervoort
Stephin J. Vervoort
SWSarah A. Welsh
Sarah A. Welsh
JDJennifer R. Devlin
Jennifer R. Devlin
EBElisa Barbieri
Elisa Barbieri
DKDeborah A. Knight
Deborah A. Knight
RJRicky W. Johnstone
Ricky W. Johnstone

1 May 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
ZFZheng Fan
Zheng Fan
JDJennifer R. Devlin
Jennifer R. Devlin
SHSimon J. Hogg
Simon J. Hogg
MDMaria A. Doyle
Maria A. Doyle
PHPaul F. Harrison
Paul F. Harrison
RJRicky W. Johnstone
Ricky W. Johnstone
CDK12 and CDK13 regulate POLII elongation rate and processivity and influence the selection of transcription termination sites.

1 January 2016 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
JDJennifer R. Devlin
Jennifer R. Devlin
KHKatherine M. Hannan
Katherine M. Hannan
NHNadine Hein
Nadine Hein
CCCarleen Cullinane
Carleen Cullinane
EKEric Kusnadi
Eric Kusnadi
RPRichard B. Pearson
Richard B. Pearson
Ribosome biogenesis and protein synthesis are dysregulated in many cancers, with those driven by the proto-oncogene c-MYC characterized by elevated Pol I–mediated ribosomal rDNA transcription and mTORC1/eIF4E-driven mRNA translation. Here, we demonstrate that coordinated targeting of rDNA transcription and PI3K–AKT–mTORC1-dependent ribosome biogenesis and protein synthesis provides a remarkable improvement in survival in MYC-driven B lymphoma. Combining an inhibitor of rDNA transcription (CX-5461) with the mTORC1 inhibitor everolimus more than doubled survival of Eμ-Myc lymphoma–bearing mice. The ability of each agent to trigger tumor cell death via independent pathways was central to their synergistic efficacy. CX-5461 induced nucleolar stress and p53 pathway activation, whereas everolimus induced expression of the proapoptotic protein BMF that was independent of p53 and reduced expression of RPL11 and RPL5. Thus, targeting the network controlling the synthesis and function of ribosomes at multiple points provides a potential new strategy to treat MYC-driven malignancies.

6 July 2016 in Oncotarget
Verified
Journal Article
Open access
JQJaclyn Quin
Jaclyn Quin
KCKeefe T. Chan
Keefe T. Chan
JDJennifer R. Devlin
Jennifer R. Devlin
Donald CameronDonald Cameron
Donald Cameron
JDJeannine Diesch
Jeannine Diesch
Ross Duncan HannanRoss Duncan Hannan
Ross Duncan Hannan
Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling

25 August 2025 in Molecular Cell
Verified
Journal Article
Open access
JDJennifer R. Devlin
Jennifer R. Devlin
BMBen Martin
Ben Martin
NBNenad Bartonicek
Nenad Bartonicek
KTKeziah Ting
Keziah Ting
ZFZheng Fan
Zheng Fan
RJRicky W. Johnstone
Ricky W. Johnstone
Controlled gene expression is achieved through the intricate regulation of RNA polymerase II (Pol II) progression through transcription-cycle checkpoints. While the contribution of CDK9 for Pol II pause-release is well established, the requirement for other cyclin-dependent kinases (CDKs) has not been fully elucidated. In this study, we propose a critical role for CDK11 in the Pol II pausing-to-elongation transition at a checkpoint that precedes and is independent from CDK9. Selective CDK11 inhibition or degradation results in acute ablation of RNA synthesis near the beginning of transcriptional units and genome-wide stalling of Pol II at transcription start site (TSS)-proximal regions. High-resolution chromatin immunoprecipitation and precision nuclear run-on assays reveal spatial differences between CDK11- and CDK9-dependent Pol II pause sites, with CDK11 regulating Pol II upstream of the CDK9 checkpoint within the pausing zone. Cancer cells exhibit profound reliance on CDK11, with CDK11 inhibition reducing tumor burden in in vivo models of blood cancer, demonstrating the importance of CDK11-dependent Pol II regulation for aggressive hematological malignancies.